Vitrectomy Devices Market

Executive Summary

Vitrectomy Devices Market was valued at US $1.85 billion in 2021 and is projected to grow at 3.05% CAGR over the forecast period to reach US $2.22 billion by 2027. Vitrectomy Devices Market represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.37 billion opportunity in 2027 over 2021.

Vitrectomy Devices from Consainsights analyses the Vitrectomy Devices Market in the Life Sciences industry over the forecast period to 2027.

Vitrectomy Devices research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Vitrectomy Devices segmentation includes Product, Application and Geography.

Based on the Product, the Vitrectomy Devices analysis covers VITRECTOMY PACKS, VITRECTOMY MACHINES, MICROSCOPIC ILLUMINATION EQUIPMENT, SURGICAL INSTRUMENTS, OTHERS.

In Product segment, VITRECTOMY PACKS segment has highest cagr growth of 2.70%.

Based on the Application, the Vitrectomy Devices analysis covers DIABETIC RETINOPATHY, RETINAL DETACHMENT, EPIRETINAL MEMBRANE, MACULAR HOLE, OTHERS (EYE INFECTIONS AND EYE INJURIES).

In Application segment, DIABETIC RETINOPATHY segment has highest cagr growth of 2.70%.

Based on the region, the Vitrectomy Devices analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include OPTOS PLC, LUMENIS LTD., TOPCON CORPORATION, NIDEK CO., LTD., LEICA MICROSYSTEMS GMBH, CARL ZEISS MEDITEC AG, ALCON, INC., IRIDEX CORPORATION, SYNERGETICS, INC, BAUSCH & LOMB INC. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, VITRECTOMY PACKS segment has the highest revenue of US $0.73 billion and is expected to grow at CAGR of 2.70% by 2027 VITRECTOMY PACKS segment has highest cagr growth of 2.70%.

VITRECTOMY PACKS

VITRECTOMY PACKS segment was valued at US $0.69 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.88 billion by 2027. VITRECTOMY PACKS segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.14 billion opportunity in 2027 over 2021.

VITRECTOMY MACHINES

VITRECTOMY MACHINES segment was valued at US $0.47 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.60 billion by 2027. VITRECTOMY MACHINES segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.10 billion opportunity in 2027 over 2021.

MICROSCOPIC ILLUMINATION EQUIPMENT

MICROSCOPIC ILLUMINATION EQUIPMENT segment was valued at US $0.35 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.44 billion by 2027. MICROSCOPIC ILLUMINATION EQUIPMENT segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

SURGICAL INSTRUMENTS

SURGICAL INSTRUMENTS segment was valued at US $0.16 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.20 billion by 2027. SURGICAL INSTRUMENTS segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $0.08 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.11 billion by 2027. OTHERS segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.02 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, DIABETIC RETINOPATHY segment has the highest revenue of US $0.77 billion and is expected to grow at CAGR of 2.70% by 2027 DIABETIC RETINOPATHY segment has highest cagr growth of 2.70%.

DIABETIC RETINOPATHY

DIABETIC RETINOPATHY segment was valued at US $0.72 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.92 billion by 2027. DIABETIC RETINOPATHY segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.15 billion opportunity in 2027 over 2021.

RETINAL DETACHMENT

RETINAL DETACHMENT segment was valued at US $0.47 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.59 billion by 2027. RETINAL DETACHMENT segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.10 billion opportunity in 2027 over 2021.

EPIRETINAL MEMBRANE

EPIRETINAL MEMBRANE segment was valued at US $0.25 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.32 billion by 2027. EPIRETINAL MEMBRANE segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.05 billion opportunity in 2027 over 2021.

MACULAR HOLE

MACULAR HOLE segment was valued at US $0.14 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.18 billion by 2027. MACULAR HOLE segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.

OTHERS (EYE INFECTIONS AND EYE INJURIES)

OTHERS (EYE INFECTIONS AND EYE INJURIES) segment was valued at US $0.16 billion in 2019 and is projected to grow at 2.70% CAGR over the forecast period to reach US $0.21 billion by 2027. OTHERS (EYE INFECTIONS AND EYE INJURIES) segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.